- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04351659
Novel Adoptive Cellular Therapy With SARS-CoV-2 Specific T Cells in Patients With Severe COVID-19
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
A novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of Coronavirus Disease 2019 (COVID-19). Currently, no vaccine or specific treatment has been proven to be effective. While waiting for vaccine to be developed, passive immunity can be acquired immediately by adoptive transfer of SARS-CoV-2 specific T cells from convalescent donors into newly infected patients.
The aim of this protocol is to demonstrate the feasibility of preparing SARS-CoV-2 specific T cells from convalescent donors for urgent clinical use. The specific hypothesis is that SARS-CoV-2 specific T cells can be isolated from the blood of convalescent donors rapidly and efficiently using SARS-CoV-2 specific peptides and an automated medical device for emergent treatment of severe COVID-19 disease.
A minimum of 8 convalescent donors will be recruited from Singapore to attain HLA sharing with at least 90% of the general population.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Michaela Seng
- Phone Number: 82487085
- Email: childhoodcancer@kkh.com.sg
Study Locations
-
-
-
Singapore, Singapore
- Recruiting
- National University Hospital
-
Contact:
- Lip Kun Tan
-
Singapore, Singapore
- Recruiting
- Singapore General Hospital
-
Contact:
- Yeh Ching Linn
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age 21 to 65
- Had a history of COVID-19 with documented positive test for SARS-CoV-2 in the past
- Has recovered from COVID-19 and is now suitable for blood donation, fulfilling all standard blood donor criteria
- Negative test for SARS-CoV-2 currently
Exclusion Criteria:
- Do not meet the standard criteria for blood cell donation at National University Hospital or Singapore General Hospital.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Blood donors
Donors who had tested positive for SARS-CoV-2 in the past and have recovered from COVID-19 and are now suitable for blood donation.
|
Donation of 1 unit of blood or leukapheresis
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Success rate in production of SARS-CoV-2 specific T cells from convalescent donor
Time Frame: Two weeks (The expected duration of donor participation is 2 weeks)
|
Success of SARS-CoV-2 specific T cell manufacturing is defined as production of >200,000 T cells per donor.
The success rate will be summarized descriptively.
|
Two weeks (The expected duration of donor participation is 2 weeks)
|
Collaborators and Investigators
Investigators
- Principal Investigator: Wing Hang Leung, KK Hospital, SingHealth, Duke-NUS
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- COVID-T 1.0
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Acute Respiratory Distress Syndrome | COVID-19-Associated Pneumonia | COVID 19 Associated Coagulopathy | COVID-19 (Coronavirus Disease 2019) | COVID-19-Associated ThromboembolismGreece
Clinical Trials on Blood donation from convalescent donor
-
National Taiwan University HospitalUnknown
-
King Fahad Specialist Hospital DammamKing Saud University; King Fahad Medical City; Taibah University; King Abdulaziz... and other collaboratorsCompletedConvalescent Plasma for COVID 19Saudi Arabia
-
Ain Shams UniversityUnknown
-
Zynex Monitoring SolutionsRecruitingBlood Loss | Fluid LossUnited States
-
Sykehuset Innlandet HFActive, not recruitingInflammation | Psychological Distress | Protein DeficiencyNorway
-
Cristina Avendaño SoláInstituto de Salud Carlos IIICompleted
-
University College, LondonKing's College London; Imperial College London; Medical Research Council; Cancer...Active, not recruiting
-
Johns Hopkins UniversityNational Institute of Allergy and Infectious Diseases (NIAID); United States... and other collaboratorsCompletedSARS-CoV 2United States
-
Fraunhofer-Institute of Toxicology and Experimental...Hannover Medical SchoolCompletedAsthma | Allergic Rhinitis
-
Queen Mary University of LondonActive, not recruitingCardiovascular Diseases | Healthy | Inflammatory DiseaseUnited Kingdom